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Transient elastography (TE) based on liver stiffness measurement (LSM) is one of the most validated noninvasive methods for liver
fibrosis staging in patients with chronic liver diseases. This method is painless, has no potential complications, is rapid (<10min),
and can be performed at the patient’s bedside. However, several points should be considered when interpreting TE results. This
review aims to discuss the critical points that might influence liver stiffness and TE results. Spectrum bias and the impact of the
prevalence of fibrosis stages should be taken into account when interpreting the studies that validated thismethod using liver biopsy
as a gold-standard. LSM might be influenced by nonfasting status, flare of transaminases, heart failure, extrahepatic cholestasis,
presence of steatosis, aetiology of liver disease, type and position of probe, and operator’s experience. In addition, interobserver
variability can impact on the management of patients with chronic liver diseases. TE should be performed by an experienced
operator (>100 exams), in a 3-hour fasting status, and its results should be handled by specialist clinicians that are aware of the
limitations of this method.
1. Introduction
Transient elastography (TE) by Fibroscan (EchoSens, Paris,
France) is one of the most widely used and validated non-
invasive methods for liver fibrosis staging [1]. This method
is painless, is not associated with potential complications,
and is well accepted by patients, especially for repeated
examinations [2]. TE is accurate for staging liver fibrosis [1]
and can be used for prediction of mortality and severe out-
come in patients with chronic liver diseases [3, 4]. However,
several points should be considered when using TE for liver
fibrosis staging to avoidmisclassification of patients [5]. Some
methodologic issues should be taken into account when
interpreting studies that validate this method. Liver stiffness
can be influenced by nonfasting status, flare of transaminases,
cardiac congestion, and extrahepatic cholestasis. In addition,
the type and position of probe and operator experience can
also impact on TE results.
2. Technical Principles of
Transient Elastography
A transducer probe transmits vibrations of mild amplitude
and low frequency (50Hz) inducing elastic shear waves that
propagate through the liver tissue. Propagation of shear
waves is followed using a pulse-echo ultrasound acquisition
measuring its velocity that is directly correlated with liver
stiffness: the stiffer the tissue is, the faster the shear wave
propagates. The examination is rapid (less than 10min) and
can easily be performed at the patient’s bedside. Briefly, the
probe is placed in an intercostal space at the intersection
between the xyphoid and the median axillary line (i.e.,
on the right lobe of the liver, usually where liver biopsy
would be performed). The operator, assisted by a time-
motion ultrasound image, locates a liver portion free of large
vascular structures and acquires the measurement (“shot”).
The software determines whether the liver stiffness measure
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(LSM) is valid or not; when a measure is invalid, it is
automatically discharged. The result of the TE represents
the median of all valid acquisitions and ranges from 2.5 to
75.0 kPa [6]. TE should be considered reliable when all the
following criteria aremet: (i) 10 successful measurements; (ii)
an interquartile range lower than 30% of the median value;
and (iii) a success rate of more than 60% [7]. In a study
that evaluated more than 13,000 TE examinations, unreliable
results were independently associated with body mass index,
lower operator experience, older age, female gender, and
metabolic factors [8].
Currently, two probes are available for staging of liver
fibrosis in adults: (i) M probe, the standard probe used in
patients with normal weight, and (ii) XL probe, used in obese
patients or when TE results with M probe are unreliable. TE
results have been described as unreliable in around 20% of
cases using the M probe [8] and in lower rates within the XL
probe [9]. In both probes liver stiffness ismeasured in volume
such as a cylinder being 4 cm high and 1 cm wide (100 times
higher than liver biopsy). Technical differences between the
M and XL probes include their central ultrasound frequency
(3.5 versus 2.5MHz), vibration amplitude (2 versus 3mm),
and the diameter of their tips (9 versus 12mm). In addition,
measures from XL probe are deeper compared to those
performed by M probe [9]. The “normal” values of TE were
defined in healthy individuals as around 5.5 kPa with the
M probe, showing that liver stiffness was higher in males
compared to females and in obese individuals compared to
those with normal weight [10, 11].
3. Critical Analysis of Diagnostic Performance
The standard expression of the effectiveness of a diagnostic
test is represented by the area under the receiver operator
characteristic curve (AUROC), which plots the sensitivity
over 1−specificity. TE is an accurate tool for stage liver fibrosis
withAUROC ranging from0.79 to 0.83 for significant fibrosis
(𝐹 ≥ 2) and from 0.95 to 0.97 cirrhosis (𝐹 = 4) in patients
with chronic liver diseases [2]. In most studies AUROC
curves for TE were calculated using liver biopsy as the gold
standard. In this context, the result represents the probability
that TE will correctly rank random patients as “significant
fibrosis or cirrhosis” or as “no fibrosis” based on liver fibrosis
[12]. This methodology leads to major issues: the assumption
that liver biopsy is binary or dichotomy, whereas fibrosis
staging uses a five-stage ordinal scale (from 𝐹0 to 𝐹4) and
the impact of diagnostic performance of noninvasive tests
based on the spectrum bias [13]. In addition, the diagnostic
performance of TE might be influenced by liver biopsy
limitations [14].
The spectrum bias and the impact of the prevalence of
fibrosis stages in AUROC estimation were demonstrated in
a study that used a serum noninvasive method (FibroTest).
AUROC values ranged from 0.67 to 0.98 according to how
“advanced fibrosis” was defined: the lowest AUROC value
was observed when only stage 𝐹2 was defined as advanced
fibrosis and only stage 𝐹1 as nonadvanced fibrosis (𝐹1 versus
𝐹2) and the maximal value was observed when the authors
evaluated 𝐹0 (defined as nonadvanced fibrosis) versus 𝐹4
(advanced fibrosis) [15]. The adjustment of AUROC values
using the Obuchowski method is an alternative to overcome
the spectrum bias and the ordinal classification of liver
biopsy [16].Thismethodology is a multinomial version of the
AUROC, with𝑁 = 5 (i.e., 𝐹0, 𝐹1, 𝐹2, 𝐹3, and 𝐹4) categories
of liver biopsy. Thus, the “weighted AUROC” (wAUROC)
by the Obuchowski method is a weighted average of the
𝑁(𝑁 − 1)/2 different curves corresponding to all pairwise
comparisons between 2× 2 of the𝑁 categories. Each pairwise
comparison is weighted according to the distance between
fibrosis stages with a penalty function proportional to the
difference in METAVIR classes between stages. This penalty
function was defined as 0.25 per difference among fibrosis
stages. When the differences between METAVIR classes are
one (i.e., 𝐹0 to 𝐹1), two (𝐹0 versus 𝐹2), three (𝐹0 versus 𝐹3),
or four stages (𝐹0 versus 𝐹4), the penalty is 0.25, 0.50, 0.75,
or 1.00, respectively.
The impact of the spectrum bias and the fact that liver
biopsy is not dichotomy were validated in a study using
TE for stage fibrosis in patients with chronic hepatitis C
(CHC) and healthy volunteers (controls). Analyzing only
patients, this study showed lower AUROC (95% CI) values
between adjacent stages [𝐹1 versus 𝐹2: AUROC = 0.613
(0.573–0.650)] than between aggregated stages [AUROC =
0.745 (0.716–0.771) for 𝐹0𝐹1 versus 𝐹2𝐹3𝐹4 and AUROC
= 0.852 (0.823–0.877) and 𝐹0𝐹1𝐹2𝐹3 versus 𝐹4, resp.]. In
addition, AUROC values for diagnosis of fibrosis stage ≥2
were higher when analyzing all individuals (patients and
controls) compared to the analysis of CHC patients without
controls [AUROC = 0.830 (0.810–0.848) versus 0.761 (0.734–
0.785), 𝑝 < 0.001]. This difference might be explained by the
fact that authors changed the prevalence of fibrosis stages in
the sample, increasing the proportion of individuals with 𝐹0
stage, by adding the controls. However, wAUROC (95% CI)
were similar in these two analyses [wAUROC= 0.894 (0.887–
0.901) versus 0.883 (0.874–0.892); 𝑝 = NS] when analyzing
CHC patients and controls versus CHC patients showing that
the Obuchowski method is not influenced by this bias [17].
The diagnostic performance [AUROC (95% CI)] of TE
with and without the Obuchowski method was recently
reported in a study with a prevalence of fibrosis stages of
54%, 30%, 9%, and 7% for 𝐹0𝐹1, 𝐹2, 𝐹3, and 𝐹4, respectively.
AUROC values were 0.874 (0.811–0.937) for 𝐹 ≥ 2 and
0.942 (0.890–0.993) for 𝐹 = 4. The wAUROC was 0.89
(0.86–0.93) when theObuchowskimethodwas used to adjust
the diagnostic performance of the noninvasive test [18]. In
addition, similar TE diagnostic performance was reported in
meta-analyses in patients with chronic hepatitis B [wAUROC
= 0.89 (0.83–0.96)] [19] and chronic hepatitis C [0.88 (0.87–
0.89)] [17] adjusted by the Obuchowski method.
4. Conditions That Lead to Overestimation of
Liver Fibrosis by TE
4.1. Flare of Transaminases. Preliminary studies reported that
severe necroinflammatory activity, such as alanine transami-
nases (ALT) greater than 10 times the upper limit of normal
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(ULN), might lead to an increase in liver stiffness and
an overestimation of fibrosis estimation [20]. More recent
studies showed that even in lesser grades of activity liver
stiffness might be overestimated. In patients with chronic
hepatitis B having the same fibrosis stage by liver biopsy,
those with ALT levels ≥2 times ULN had higher TE results
compared to those with normal transaminases (9.5 versus
4.7 kPa, 𝑝 > 0.001) [21]. This hypothesis was validated by
analyzing a significant decrease in liver stiffness values after a
3-month antiviral treatment in chronic hepatitis B compared
to pretreatment levels (7.9 versus 6.4 kPa; 𝑝 < 0.001) [22].
Patients had elevated transaminases that normalized after 3-
month antiviral treatment and the time between first and
secondmeasureswas a very short delay to consider regression
of liver fibrosis. Similar results were reported in chronic
hepatitis C: considering patients with fibrosis stages ≥F3
identified by liver biopsy, those with important necroin-
flammatory activity (𝐴2𝐴3𝐴4) had higher liver stiffness
measurements compared to those without activity (𝐴0𝐴1)
[14.6 versus 6.2 kPa; 𝑝 < 0.05] [23].
4.2. Extrahepatic Cholestasis and Liver Congestion. Liver stiff-
ness values increase in extrahepatic cholestasis independently
of fibrosis status. Studies reported that liver stiffness highly
correlates with total bilirubin levels (Spearman’s correlation
𝑟 = 0.67 and 0.69) and decreases after successful biliary
drainage (from 10.8 to 7.1 kPa and 7.6 to 5.4 kPa in both
studies) [24, 25]. The reasons underlying the high stiffness
in cholestasis are unknown but could be related to tissue
swelling, inflammation, edema, and increased intracellular
pressure due to impaired bile flow. In addition, the increased
hydrostatic pressure alone seems to contribute to increased
liver stiffness during extrahepatic cholestasis [24].
Hepatic congestion might increase liver stiffness mea-
surements leading to an overestimation of fibrosis and
a misclassification of cirrhosis. In a case-report, authors
showed a significant decrease of liver stiffness after a cardiac
transplant (44.3 versus 3.8 kPa; 𝑝 < 0.0001) in a patient
with chronic heart failure. This hypothesis was validated
in few studies that evaluated TE in patients with cardiac
dysfunction and controls. Liver stiffness measurements were
significantly higher in patients with heart failure than in
controls and decreased during hospitalization after control of
cardiac disease [26]. In addition, liver stiffness was increased
in patients with right-sided heart failure compared to healthy
controls [9.7 (IQR 5.0–10.8) kPa versus 4.4 (3.6–5.1) kPa, 𝑝 <
0.001] [27]. These findings can be explained by worsening
cardiac dysfunction increasing hepatic vein pressure leading
to intrahepatic blood stasis and higher liver stiffness.
4.3. Nonfasting Status. Liver stiffness measurement signif-
icantly increased immediately after food intake (6.0 ± 2.1
versus 4.9± 2.1 kPa;𝑝 < 0.001) in patients with no fibrosis and
moderate fibrosis (8.2 ± 2.3 versus 7.2 ± 1.3 kPa; 𝑝 = 0.008). In
addition, TE results normalized 180min after meal [28]. The
impact of nonfasting status on liver stiffness was validated in
patients with CHC: an increase in liver stiffness was observed
15 to 45 minutes after the onset of the meal with return to
baseline premeal levels within 120 minutes [29].These results
reinforce that TE should be performed in 120 to 180min
fasting status.
4.4. Liver Steatosis. Liver steatosis might impact in TE lead-
ing to an overestimation of liver fibrosis. Liver stiffness values
were significantly higher in subjects with severe steatosis
(≥66% at liver biopsy) compared to those without (𝐹0-𝐹1
6.9 versus 5.8 kPa, 𝑝 = 0.04; 𝐹0–𝐹2 7.4 versus 6.0 kPa,
𝑝 = 0.001) in a study with biopsy-proven patients with
nonalcoholic fatty liver disease. In addition, a higher rate
of false-positive TE results was observed in patients with
steatosis ≥66% compared to those without (𝐹0-𝐹1 23.6%
versus 14.9%, 𝐹0–𝐹2 33.3% versus 13.2%) [30]. Similar results
were observed in patients with CHC: amongst patients within
the same fibrosis stages (𝐹0–𝐹2 and 𝐹3-𝐹4; 𝐹0–𝐹3 and
𝐹4), mean liver stiffness values were significantly higher in
subjectswithmoderate-severe steatosis (≥20%at liver biopsy)
compared to those without [31].
5. Other Factors That Might Impact on
Transient Elastography Results
5.1. Operator Effect. TE reliability and its diagnostic perfor-
mance might be influenced by the operator’s experience. The
experience of the operator was independently associated with
unreliability of this method in a study that analyzed more
than 13,000 examinations [8]. An operator effect in TE was
validated in a study that used FibroTest as the reference: the
diagnostic performance of TE was significantly better when
examinations performed by the nonexperimented operator
were excluded (AUROC = 0.80 versus 0.70; 𝑝 = 0.009)
[7]. The performance of at least 100 examinations should be
considered to define an experienced operator [32].
5.2. Interobserver Variability. Controversial results have been
described in recent years on reproducibility of TE. The first
study reported a high intraclass correlation coefficient [ICC
= 0.990 (95% CI 0.977–0.987)] [33]. Besides the description
of similar results, other authors showed 25% of discordance
of at least one stage of liver fibrosis by TE performed
by experienced operators [34]. This relatively high rate of
classification of fibrosis stages was reported in more recent
studies [32, 35–37]. Both examinations were performed by
an experienced operator, were well correlated, and presented
high ICC values. However, these studies reported a rate from
20 to 30% discrepancy of at least one stage of fibrosis. We
are aware that it is very difficult, even with liver biopsy,
to distinguish between intermediate adjacent fibrosis stages
(i.e.; 𝐹2 versus 𝐹3) [38]. However, this variability of at least
one stage of fibrosis might impact on the management of
patients with chronic liver disease. The correct classification
of fibrosis stage might impact on access to new direct-acting
antiviral (DAA) treatment for patients with CHC or duration
of treatment [39].This variabilitymight be associatedwith the
choice of intercostal space or probe position [40] or might be
related to the TE technique itself and a few factors that cannot
be controlled during examination. TE results performed in
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a longitudinal follow-up (repeated measurements) might be
more accurate than a single measure and interobserver vari-
abilitymight beminimizedwhenTEmeasures are performed
by the same experienced operator during follow-up [41].
5.3. Other Factors. Liver stiffness might also be impacted
by the aetiology of the chronic liver disease. Patients with
cholestatic liver diseases, such as primary biliary cirrhosis and
primary sclerosing cholangitis, seem to have higher stiffness
than those with viral hepatitis. Therefore, for each stage of
fibrosis, cutoffs are higher than in chronic viral hepatitis
either because of the nature of the liver disease or because of
cholestasis [2]. Similar higher cutoffs for each fibrosis stage
were described in alcoholic liver disease [42]. There is no
evidence that presence of hepatocellular carcinoma might
impact on liver stiffness. However, TE has a prognostic value
to predict the development of liver neoplasm [43].
6. Conclusions
Liver stiffness might be influenced by nonfasting status, flare
of transaminases, heart failure, extrahepatic cholestasis, and
presence of severe steatosis leading to an overestimation
of liver fibrosis. In addition, a not negligible interobserver
variability can also impact on management of patients with
chronic liver diseases. The prevalence of fibrosis stages and
the fact that liver biopsy is not dichotomy might have
impacted on the diagnostic performance of the test. Transient
elastography should be performed by an experienced opera-
tor (>100 exams), in a fasting status, and its results should be
handled by specialist clinicians that are aware of limitations
of this method.
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